Segments - Reconciliation of Revenue (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenue	$ 244,293,000	$ 148,211,000	[1]
Adjusted EBITDA	186,992,000	100,896,000
Nucleic Acid Production
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenue	223,650,000	123,932,000
Biologics Safety Testing
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenue	20,643,000	17,649,000
Protein Detection
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenue		6,630,000
Operating Segments | Nucleic Acid Production
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenue	223,650,000	124,169,000
Adjusted EBITDA	182,799,000	95,032,000
Operating Segments | Biologics Safety Testing
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenue	20,643,000	17,649,000
Adjusted EBITDA	16,532,000	14,287,000
Operating Segments | Protein Detection
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenue		6,630,000
Adjusted EBITDA		1,959,000
Corporate
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenue	0	0
Adjusted EBITDA	(12,339,000)	(10,336,000)
Eliminations
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenue	0	(237,000)
Adjusted EBITDA	$ 0	$ (46,000)

[1] As adjusted to reflect the impact of the adoption of Accounting Standards Codification 842 (“ASC 842”). See Note 1 to the condensed consolidated financial statements for a summary of the adjustments.